ArticleNeuro-oncology practice2025
Neighborhood disadvantage is associated with treatment access outcomes and survival among individuals with a primary brain tumor.
Article in Neuro-oncology practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02851706 (Evaluation of the Natural History of and Specimen Banking for Patients With Tumors of the Central Nervous System), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Natural History of and Specimen Banking for Patients With Tumors of the Central Nervous System
Who cites it
3 citing papers in PubMed.
- Equity in Neurotoxicity Care in the Era of Cancer Immunotherapy.Seminars in neurology · 2026Article
- Natural history study of adults with primary central nervous system tumors: Initial results for first 1000 participants.Neuro-oncology practice · 2026Article
- The impact of neighborhood-level disadvantage on symptoms, mood, and health-related quality of life among the primary brain tumor population.Neuro-oncology practice · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Background: Neighborhood disadvantage is linked to lower rates of healthcare access. To understand how residence affects the primary brain tumor (PBT) population, we assessed neighborhood disadvantage and population density with treatment access outcomes among a cohort of 666 adult participants with a PBT and study entry data in a large observational study at the National Institutes of Health (NIH) (NCT#: NCT02851706). Methods: We assessed neighborhood disadvantage (measured by the area deprivation index [ADI]) and population density with symptom duration before diagnosis and time to treatment using ordinal logistic and linear regression. Kaplan-Meier survival curves were estimated by population density and ADI, overall and stratified by residential distance to the NIH, tumor grade, and age. Results: Among 666 participants, 24% lived in more disadvantaged areas. Among the overall sample, there were no associations between ADI or population density with symptom duration, but the time to any treatment was longer for patients living in more disadvantaged neighborhoods ( Conclusions: Individuals with low-grade PBTs living in more disadvantaged neighborhoods and further from NIH had a longer time to treatment. Future efforts should focus on strategies to reach patients living in disadvantaged neighborhoods.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.